IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11912659 B1

PDFFull Text
Date of Patent:
Feb. 27, 2024

Filed:

Apr. 16, 2021

Ebna1 inhibitors and methods using same

Applicant:

The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US);

Inventors:

Troy E. Messick, Upper Darby, PA (US);

Garry R. Smith, King of Prussia, PA (US);

Allen B. Reitz, Lansdale, PA (US);

Paul M. Lieberman, Wynnewood, PA (US);

Mark E. McDonnell, Lansdale, PA (US);

Yan Zhang, Fort Washington, PA (US);

Marianne Carlsen, Yardley, PA (US);

Shuai Chen, Philadelphia, PA (US);

Assignee:

The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US);

Attorneys:

Saul Ewing LLP

Kathryn Doyle

Domingos J. Silva

Primary Examiner:

David K O'Dell

Int. Cl.
CPC ...
C07D 209/08 (2006.01); C07D 403/12 (2006.01); C07D 405/14 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 487/08 (2006.01); C07D 471/08 (2006.01); C07D 417/12 (2006.01); A61P 35/00 (2006.01); A61P 31/20 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4155 (2006.01); A61K 31/422 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/433 (2006.01); A61K 31/435 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/551 (2006.01); A61K 45/06 (2006.01); C07D 277/62 (2006.01); C07D 401/10 (2006.01); C07D 401/14 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 413/10 (2006.01); C07D 417/10 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 491/107 (2006.01);
U.S. Cl.
CPC ...
C07D 209/08 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/4155 (2013.01); A61K 31/422 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/433 (2013.01); A61K 31/435 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/551 (2013.01); A61K 45/06 (2013.01); A61P 31/20 (2018.01); A61P 35/00 (2018.01); C07D 277/62 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 413/10 (2013.01); C07D 417/10 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 471/08 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 491/107 (2013.01);
Abstract

The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

Find Patent Forward Citations

Loading…